Search This Blog

Saturday, April 10, 2021

Psychotherapy Now Most Common Telehealth Procedure

 One-hour psychotherapy sessions became the most common telehealth service nationwide this January, according to a recent data analysis.

The data, collected monthly by FAIR Health -- a New York City-based nonprofit specializing in health insurance data collection -- showed that psychotherapy had been the second or third most common telehealth service throughout 2020, depending on the month. But in January of this year, for the first time since the pandemic began, it secured the top spot across the country.

Mental health conditions have consistently made up the largest number of telehealth diagnoses since 2019. But, according to FAIR Health's data analysis, the numbers jumped from 30% nationally in January 2020, to 51.3% in January 2021.

Among most regions of the U.S., with the exception of the West Coast, the most common diagnosis was generalized anxiety disorder, making up nearly 30% of mental health claims. For the West, major depressive disorder had the highest diagnosis rate.

These numbers don't come as a surprise to psychologist Kathryn Esquer, PsyD, who created an online network, called the Teletherapist Network, for therapists transitioning into telehealth during the pandemic.

"We've been seeing not only existing clientele increase frequency because their symptoms of anxiety or depression have been worsening over the past year, but we're also experiencing an unprecedented amount of new clients asking for help," Esquer told MedPage Today.

Esquer and her teletherapist colleagues have noticed that existing clients have been booking more sessions than usual, and have been staying in those sessions for longer periods of time than before telehealth appointments became ubiquitous. Now, many of the psychologists in her network have reached their maximum capacity of clients, struggling to find referrals to other counselors or clinicians with the bandwidth to take them on.

Despite her lack of shock -- from both her own experience in the past year and from her colleagues' feedback -- that 60-minute psychotherapy has become the most commonly practiced telehealth procedure, seeing that fact reflected in the numbers brought Esquer a sense of comfort.

"It was really validating as a therapist who has been working way more hours, seeing way more patients -- to see those numbers show up," Esquer said. "I'm not the only one who's experiencing this high level of demand."

The source of these data comes from FAIR Health's trove of private healthcare claims data. According to president Robin Gelburd, they have the nation's largest collection of this type of data, including over 33 billion claims records.

"FAIR Health data are submitted by over 60 national and regional payers and third-party administrators who insure or process claims for private insurance plans, covering individuals located in 493 regions across all 50 states; Washington, D.C.; Puerto Rico; and the U.S. Virgin Islands," Gelburd wrote in an email to MedPage Today.

Esquer and many members of her network plan to continue using telehealth, or a hybrid blend of in-person and online sessions, even as more and more people become vaccinated for COVID-19; FAIR Health will also continue tracking telehealth data to see how the trends change going forward.

"Policymakers, payers, providers, patients, and other healthcare stakeholders will be interested in whether telehealth maintains its growth without the pandemic to drive it," Gelburd wrote. "They will also want to know in what directions it evolves."

https://www.medpagetoday.com/special-reports/exclusives/92029

Georgia site is 4th in US to pause Johnson & Johnson vaccine

 A coronavirus vaccine site in Georgia became the fourth US location this week to pause its administration of the Johnson & Johnson jab after concerns over possible adverse reactions, a report said.

Eight people experienced lightheadedness after getting the shot Wednesday at the Cumming Fairgrounds, though health officials believe that could have simply been caused by the hot weather, WSB-TV reported.

“It was a fainting issue,” Dave Palmer, North Georgia Health District spokesperson, told the outlet.

“We don’t think it’s anything to do with the vaccine. It’s probably more environmental factors,” Palmer said.

Adverse reactions were incurred by less than 2% of the 435 people who received the vaccine at the site, the report said.

“That facility is hard to cool, and we do have fans there, but it was a warmer day,” Palmer told the station. “I think the heat may have had some bearing on it. We’re not sure.”

The Johnson & Johnson vaccine was also halted in the past week at sites in Colorado, North Carolina and Iowa.

https://nypost.com/2021/04/10/georgia-is-the-fourth-state-to-pause-johnson-johnson-vaccine/

Judge hands Amazon a setback in NY lawsuit over COVID-19 shortfalls

 

A federal judge on Friday ruled against Amazon.com Inc as the company defends against New York Attorney General Letitia James' lawsuit claiming it prioritized profit over worker safety during the COVID-19 pandemic at two New York City warehouses.

U.S. District Judge Jed Rakoff in Manhattan granted James' request to return her lawsuit to a New York state court, and rejected Amazon's bid to move it to Brooklyn federal court, where the online retailer had sued James to stop her from suing.

James accused Amazon of ignoring its duty to take reasonable steps to protect workers from the coronavirus at a Staten Island fulfillment center and a Queens distribution center, and retaliating against workers who complained.

An Amazon spokeswoman declined to comment. Rakoff said he will explain the reasoning behind his two-paragraph order later.

"Amazon has forced its employees to work in unsafe conditions throughout this pandemic," James said in welcoming her lawsuit's move back to state court, "where it belongs."

While the ruling did not address the dispute's merits, it is a setback for Seattle-based Amazon, which accused James of overstepping her authority and said federal laws rather than New York's should govern workplace safety.

Amazon said both lawsuits belonged in the Brooklyn court because Queens and Staten Island are in that jurisdiction, and suing in different courts was wasteful.

James said Amazon had "cut corners" in protecting workers because doing more could threaten productivity, sales volume and profitability.

She said she had authority to enforce New York state law "to promote proper business conduct and ensure that current and future Amazon employees have a safe and honest workplace."

Her lawsuit seeks improved worker protections, and damages for two Amazon workers who allegedly faced retaliation.

One, Christian Smalls, was fired one year ago, purportedly for violating a paid quarantine when leading a protest over conditions at the Staten Island warehouse.

James sued Amazon on Feb. 16, four days after Amazon sued her. Amazon then moved James' lawsuit to federal court.

https://www.marketscreener.com/quote/stock/AMAZON-COM-INC-12864605/news/Amazon-com-nbsp-Judge-hands-Amazon-a-setback-in-New-York-lawsuit-over-COVID-19-shortfalls-32928631/

China's COVID-19 vaccine output projected to hit 3 billion by year-end

 China’s will likely have produced 3 billion doses of COVID-19 vaccines by the end of the year, a National Health Commission official said on Saturday.

Zheng Zhongwei, who also heads a team coordinating the country’s COVID-19 vaccine development projects, made the comment during an industry event in the city of Chengdu in southwestern China’s Sichuan province.

“In the second half of this year, we are fully capable of meeting our own demand,” Zheng said.

Though manufacturers are rapidly expanding production capacity, it is unclear if output has risen as fast. Production tripled from Feb. 1 through late March to 5 million doses a day, the government said its most recent update.

Leading vaccine manufacturer Sinovac Biotech said this month it had doubled its annual production capacity to 2 billion doses after completing its third production facility.

The China National Pharmaceutical Group (Sinopharm) also has a combined annual production capacity of at least 1.1 billion for two separate vaccines. The company has said it aims to raise capacity to 3 billion but has not specified a timeframe.

Sinopharm said on Friday that it will be able to supply 100 million COVID-19 vaccines a month starting from April.

https://www.reuters.com/article/us-health-coronavirus-china-vaccination/chinas-covid-19-vaccine-output-to-hit-3-billion-by-year-end-official-idUSKBN2BX06B

Curevac says May approval for COVID-19 vaccine possible

 German biotech firm Curevac believes the European Union might give approval for its COVID-19 vaccine in May or June, a spokesman was quoted as saying in the Augsburger Allgemeine newspaper on Saturday.

"We are already very advanced in Phase Three clinical trials and are expecting the data for the final approval package," spokesman Thorsten Schueller told the paper.

Previously, approval was expected in June.

Curevac still plans to produce up to 300 million vaccine doses this year, the spokesman was quoted as saying.

https://www.marketscreener.com/news/latest/Curevac-says-May-approval-for-COVID-19-vaccine-possible-newspaper--32929513/

Neuropilin-1 (NRP1) as novel SARS-CoV-2 host cell entry mediator implicated in COVID-19

 

  • Ioannis Kyrou
  • Harpal S. Randeva
  • Demetrios A. Spandidos &
  •  
  • Emmanouil Karteris

    DOI: https://doi.org/10.1038/s41392-020-00460-9

    PDF: https://www.nature.com/articles/s41392-020-00460-9.pdf

    Two recently published studies published in Science by Daly et al.1 and Cantuti-Castelvetri et al.2 identified neuropilin-1 (NRP1) as an additional cellular mediator which may facilitate the entry of the new severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 (SARS-CoV-2) into host cells. The findings of these elegant studies collectively indicate that, in addition to the role of angiotensin-converting enzyme 2 (ACE2) in mediating the cellular entry of SARS-CoV-2, NRP1 may act as a host cell mediator that can increase the infectivity and may thus contribute to the tissue/organ tropism of this coronavirus.

    Increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinees

     Talia Kustin, Noam Harel, Uriah Finkel, Shay Perchik, Sheri Harari, Maayan Tahor, Itamar Caspi, Rachel Levy, Michael Leschinsky, Shifra Ken Dror, Galit Bergerzon, Hala Gadban, Faten Gadban, Eti Eliassian, Orit Shimron, Loulou Saleh, Haim Ben-Zvi, Doron Amichay, Anat Ben-Dor, Dana Sagas, Merav Strauss, Yonat Shemer Avni, Amit Huppert, Eldad Kepten, Ran D Balicer, Doron Nezer, Shay Ben-Shachar,